KRAS and carcinoma: Of note, this represents the first time that effective impairment of K-Ras+/G12Vp53−/− carcinomas is achieved, as genetic abrogation of other therapeutic pathways did not impair tumor growth in the absence of p53 (Navas et al, 2012).